Literature DB >> 29143117

The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.

Maryam Rezaei1, Jiahui Cao1, Katrin Friedrich2, Björn Kemper3, Oliver Brendel2, Marianne Grosser2, Manuela Adrian1, Gustavo Baretton2, Georg Breier4, Hans-Joachim Schnittler5.   

Abstract

The cadherin switch has profound consequences on cancer invasion and metastasis. The endothelial-specific vascular endothelial cadherin (VE-cadherin) has been demonstrated in diverse cancer types including breast cancer and is supposed to modulate tumor progression and metastasis, but underlying mechanisms need to be better understood. First, we evaluated VE-cadherin expression by tissue microarray in 392 cases of breast cancer tumors and found a diverse expression and distribution of VE-cadherin. Experimental expression of fluorescence-tagged VE-cadherin (VE-EGFP) in undifferentiated, fibroblastoid and E-cadherin-negative MDA-231 (MDA-VE-EGFP) as well as in differentiated E-cadherin-positive MCF-7 human breast cancer cell lines (MCF-VE-EGFP), respectively, displayed differentiation-dependent functional differences. VE-EGFP expression reversed the fibroblastoid MDA-231 cells to an epithelial-like phenotype accompanied by increased β-catenin expression, actin and vimentin remodeling, increased cell spreading and barrier function and a reduced migration ability due to formation of VE-cadherin-mediated cell junctions. The effects were largely absent in both MDA-VE-EGFP and in control MCF-EGFP cell lines. However, MCF-7 cells displayed a VE-cadherin-independent planar cell polarity and directed cell migration that both developed in MDA-231 only after VE-EGFP expression. Furthermore, VE-cadherin expression had no effect on tumor cell proliferation in monocultures while co-culturing with endothelial cells enhanced tumor cell proliferation due to integration of the tumor cells into monolayer where they form VE-cadherin-mediated cell contacts with the endothelium. We propose an interactive VE-cadherin-based crosstalk that might activate proliferation-promoting signals. Together, our study shows a VE-cadherin-mediated cell dynamics and an endothelial-dependent proliferation in a differentiation-dependent manner.

Entities:  

Keywords:  Breast cancer; Cell migration; Epithelial–mesenchymal transition; Tumor progression; VE-cadherin

Mesh:

Substances:

Year:  2017        PMID: 29143117     DOI: 10.1007/s00418-017-1619-8

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  63 in total

1.  Endothelial barrier function under laminar fluid shear stress.

Authors:  J Seebach; P Dieterich; F Luo; H Schillers; D Vestweber; H Oberleithner; H J Galla; H J Schnittler
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

2.  Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

Authors:  Daisy W J van der Schaft; Femke Hillen; Patrick Pauwels; Dawn A Kirschmann; Karolien Castermans; Mirjam G A Oude Egbrink; Maxine G B Tran; Rafael Sciot; Esther Hauben; Pancras C W Hogendoorn; Olivier Delattre; Patrick H Maxwell; Mary J C Hendrix; Arjan W Griffioen
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 3.  Epithelial cell-cell junctions and plasma membrane domains.

Authors:  Ben N G Giepmans; Sven C D van Ijzendoorn
Journal:  Biochim Biophys Acta       Date:  2008-07-28

Review 4.  VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity.

Authors:  Monica Giannotta; Marianna Trani; Elisabetta Dejana
Journal:  Dev Cell       Date:  2013-09-16       Impact factor: 12.270

Review 5.  The relevance of EMT in breast cancer metastasis: Correlation or causality?

Authors:  Ruben Bill; Gerhard Christofori
Journal:  FEBS Lett       Date:  2015-05-12       Impact factor: 4.124

6.  Caveolin-1 opens endothelial cell junctions by targeting catenins.

Authors:  Romy Kronstein; Jochen Seebach; Sylvia Grossklaus; Carsten Minten; Britta Engelhardt; Marek Drab; Stefan Liebner; Yvan Arsenijevic; Abdallah Abu Taha; Tatiana Afanasieva; Hans-Joachim Schnittler
Journal:  Cardiovasc Res       Date:  2011-09-29       Impact factor: 10.787

7.  Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.

Authors:  Daniela Alfano; Giuseppina Votta; Almut Schulze; Julian Downward; Mario Caputi; Maria Patrizia Stoppelli; Ingram Iaccarino
Journal:  Mol Cell Biol       Date:  2010-02-01       Impact factor: 4.272

8.  Myosin II activity dependent and independent vinculin recruitment to the sites of E-cadherin-mediated cell-cell adhesion.

Authors:  Grant M Sumida; Tyler M Tomita; Wenting Shih; Soichiro Yamada
Journal:  BMC Cell Biol       Date:  2011-11-03       Impact factor: 4.241

9.  Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion.

Authors:  Simon A Fry; Claire E Robertson; Ruth Swann; Miriam V Dwek
Journal:  Br J Cancer       Date:  2016-03-24       Impact factor: 7.640

10.  Rnd3 as a Novel Target to Ameliorate Microvascular Leakage.

Authors:  Jerome W Breslin; Dayle A Daines; Travis M Doggett; Kristine H Kurtz; Flavia M Souza-Smith; Xun E Zhang; Mack H Wu; Sarah Y Yuan
Journal:  J Am Heart Assoc       Date:  2016-04-05       Impact factor: 5.501

View more
  9 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2017-12-07       Impact factor: 4.304

2.  Machine Learning with Optical Phase Signatures for Phenotypic Profiling of Cell Lines.

Authors:  Van K Lam; Thanh Nguyen; Thuc Phan; Byung-Min Chung; George Nehmetallah; Christopher B Raub
Journal:  Cytometry A       Date:  2019-04-22       Impact factor: 4.355

3.  MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells.

Authors:  Xiaorui Wang; Zhongsheng Tong; Hong Liu
Journal:  Onco Targets Ther       Date:  2019-09-18       Impact factor: 4.147

4.  Label-Free Digital Holographic Microscopy for In Vitro Cytotoxic Effect Quantification of Organic Nanoparticles.

Authors:  Kai Moritz Eder; Anne Marzi; Álvaro Barroso; Steffi Ketelhut; Björn Kemper; Jürgen Schnekenburger
Journal:  Cells       Date:  2022-02-12       Impact factor: 6.600

5.  Morphology, Motility, and Cytoskeletal Architecture of Breast Cancer Cells Depend on Keratin 19 and Substrate.

Authors:  Van K Lam; Pooja Sharma; Thanh Nguyen; Georges Nehmetallah; Christopher B Raub; Byung Min Chung
Journal:  Cytometry A       Date:  2020-04-14       Impact factor: 4.355

6.  The Influence of VE-Cadherin on Adhesion and Incorporation of Breast Cancer Cells into Vascular Endothelium.

Authors:  Thomas Brock; Elisabeth Boudriot; Anke Klawitter; Marianne Großer; Trang T P Nguyen; Sindy Giebe; Erik Klapproth; Achim Temme; Ali El-Armouche; Georg Breier
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

7.  The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.

Authors:  Marianna Talia; Ernestina Marianna De Francesco; Damiano Cosimo Rigiracciolo; Maria Grazia Muoio; Lucia Muglia; Antonino Belfiore; Marcello Maggiolini; Andrew H Sims; Rosamaria Lappano
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

8.  Exploiting the potential of commercial digital holographic microscopy by combining it with 3D matrix cell culture assays.

Authors:  Monica Hellesvik; Hanne Øye; Henriette Aksnes
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

9.  Automated interpretation of time-lapse quantitative phase image by machine learning to study cellular dynamics during epithelial-mesenchymal transition.

Authors:  Lenka Strbkova; Brittany B Carson; Theresa Vincent; Pavel Vesely; Radim Chmelik
Journal:  J Biomed Opt       Date:  2020-08       Impact factor: 3.170

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.